Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
Published Date: 1/7/2025
Notice
Summary
The FDA just dropped a draft guide to help companies make and sell medical devices with AI software. It explains what info to include so the FDA can check these devices are safe and work well, plus tips on managing them from start to finish. If you’re in the AI medical device game, get ready to share your thoughts by April 7, 2025, before the rules get final—and yes, this could affect your product plans and budgets.
Analyzed Economic Effects
6 provisions identified: 6 benefits, 0 costs, 0 mixed.
Marketing submission documentation guidance
The draft guidance explains what documentation sponsors should include in marketing submissions for devices that include AI-enabled software functions to support FDA's evaluation of safety and effectiveness. It is guidance to help manufacturers prepare the material the FDA will review.
Total product lifecycle (TPLC) recommendations
The draft guidance proposes recommendations for the design, development, and implementation of AI-enabled devices throughout the total product lifecycle (TPLC). Manufacturers may use these recommendations from early development through decommissioning.
Transparency and bias evidence expectations
The draft guidance sets out FDA's current thinking on strategies to address transparency and bias, including collecting evidence to evaluate whether a device benefits relevant demographic groups (for example, race, ethnicity, sex, and age) similarly. The goal is to help ensure AI-enabled devices remain safe and effective for their intended use across groups.
Postmarket performance monitoring plan
The draft guidance proposes an approach to postmarket performance monitoring for AI-enabled devices, including using a performance monitoring plan as a risk mitigation tool. FDA highlights performance monitoring as part of managing device risk after marketing.
Opportunity to comment by April 7, 2025
FDA is accepting public comments on the draft guidance and requests that electronic or written comments be submitted by April 7, 2025 so the Agency can consider them before it begins work on the final guidance. Comments may be submitted via https://www.regulations.gov (Docket No. FDA-2024-D-4488) or as written/paper submissions per the notice.
Draft guidance is nonbinding
The document states the draft guidance, if finalized, will represent FDA's current thinking but is not binding, and that alternative approaches that satisfy statutes and regulations may be used. The draft guidance is not for implementation at this time.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-20724, Notice of Intent To Prepare a Supplemental Environmental Impact Statement for the Sentinel Deployment and Minuteman III Decommissioning and Disposal
The Air Force is updating its plan to replace old Minuteman III missiles with new Sentinel missiles across five states, including Wyoming, Montana, and North Dakota. They’re checking how these changes might affect the environment and want your thoughts during a 30-day comment period starting now. This update could impact local lands and communities, with careful reviews to keep things safe and smart.
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20708, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Amend the IEX Equities Fee Schedule
IEX is shaking up its fee schedule starting November 1, 2026, by tweaking who gets rebates for adding displayed liquidity and changing rebate amounts. This affects IEX members who trade stocks, giving them new ways to save or earn more on fees. The changes kick in right away after filing, so traders should get ready to adjust their strategies and cash flow.
2026-20710, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Modify the Required Criteria To Qualify for the Reduced Incremental Fee
Investors Exchange (IEX) is changing the rules for who can get a discount on certain trading fees. Starting November 1, 2026, members will need to meet new criteria to qualify for the reduced incremental fee, which could save or cost them money depending on their trading activity. This change affects all IEX members and kicks in right away to keep things fair and clear.
2026-20779, Passenger Vehicle and Light Truck Tires From Thailand: Preliminary Results and Rescission, in Part, of Antidumping Duty Administrative Review; 2024-2025
The U.S. Department of Commerce found that tires from Thailand were sold in the U.S. for less than their normal price between July 2024 and June 2025. This means some importers might have to pay extra duties to keep things fair. The review process had some delays due to government shutdowns, but now the preliminary results are out and open for comments.
2026-20763, National Environmental Policy Act Implementing Procedures: Wintertime Oil and Gas Exploration in the National Petroleum Reserve in Alaska Categorical Exclusion
Starting October 9, 2026, the Department of the Interior is making it easier and faster to approve wintertime oil and gas exploration in Alaska’s National Petroleum Reserve by adding a special rule that skips some usual paperwork. This change mainly affects energy companies working in the area and aims to speed up projects while still protecting the environment. No new costs are expected, but the process will be smoother and quicker.
Previous / Next Documents
Previous: 2024-31542, Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry; Availability; Comment Request
The FDA is rolling out a draft guide to help drug and biological product makers use artificial intelligence (AI) safely and smartly when making decisions about their products. This affects companies working on medicines and biologics, aiming to boost safety and quality without slowing things down. Comments on this guide are open until April 7, 2025, so industry folks have time to weigh in before the final rules drop.
Next: 2024-31544, Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Availability
The FDA just dropped new rules to help companies that handle human cells and tissues keep tuberculosis (TB) from spreading. These rules tell them how to check donors for TB risks and what extra steps to take until better TB tests are ready. This change starts right away and helps protect everyone who gets these medical products without adding big costs.